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Background: Continuous flow Left Ventricular Assist Device (LVAD) implantation as bridge to transplant (BTT) is highly successful. However, LVADs 
can elevate anti-Human Leukocyte Antigen antibody (HLA-Ab) levels posing a barrier to transplantation. We describe the incidence and pattern of 
allosensitization in LVAD patients.
Methods: Patients undergoing LVAD implant as BTT (2008-2011) had HLA-Ab levels assessed using HLA class I and II phenotypes and single 
antigens on the Luminex platform. Calculated PRA (cPRA) was determined based on HLA-Ab levels consistent with a positive cytotoxic crossmatch.
Results: We included 52 patients in our study. The mean age was 54, 73% were male, and 71% had a dilated cardiomyopathy. Each patient had 
an average of 2.6 units transfused. Of the 14 women, 71% were multiparous. The cohort was divided into 3 groups. Group I (n=43) had a negative 
cPRA pre and post implant. Group II (n=6) had a negative cPRA pre implant and increased cPRA (>25) post implant. Group III (n=3) had an elevated 
cPRA (>50) pre implant and remained elevated and was excluded from analysis. Female gender was a predictor of a post-op cPRA rise (p=0.001). In 
group II, 83% had a reduction in cPRA within 8 months.
Conclusion: A minority of patients who received a LVAD as BTT had an increase in cPRA post implant. Most patients that had a negative cPRA pre 
implant decreased without intervention. Those that had an elevated cPRA pre implant experienced persistent elevation post implant.
